Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
immunotherapy
lymphoma
receptors, chimeric antigen
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
accepted:
04
10
2023
medline:
27
10
2023
pubmed:
26
10
2023
entrez:
25
10
2023
Statut:
ppublish
Résumé
Chimeric antigen receptor T-cell therapy (CART) is effective for patients with refractory or relapsed lymphoma with prolongation of survival. We aimed to improve the prediction of Lugano criteria for overall survival (OS) at 30-day follow-up (FU1) by including the pre-infusion tumor growth rate (TGR Consecutive patients with pre-baseline (pre-BL), baseline (BL) and FU1 imaging with CT or positron emission tomography/CT before CART were included. TGR was defined as change of Lugano criteria-based tumor burden between pre-BL, BL and FU1 examinations in relation to days between imaging examinations. Overall response and progression-free survival were determined based on Lugano criteria. Proportional Cox regression analysis studied association of TGR with OS. For survival analysis, OS was analyzed using Kaplan-Meier survival curves. Fifty-nine out of 81 patients met the inclusion criteria. At 30-day FU1 8 patients (13.6%) had a complete response (CR), 25 patients (42.4%) a partial response (PR), 15 patients (25.4%) a stable disease (SD), and 11 patients (18.6%) a progressive disease (PD) according to CT-based Lugano criteria. The median TGR In the context of CART, the additional use of TGR
Sections du résumé
BACKGROUND
Chimeric antigen receptor T-cell therapy (CART) is effective for patients with refractory or relapsed lymphoma with prolongation of survival. We aimed to improve the prediction of Lugano criteria for overall survival (OS) at 30-day follow-up (FU1) by including the pre-infusion tumor growth rate (TGR
METHODS
Consecutive patients with pre-baseline (pre-BL), baseline (BL) and FU1 imaging with CT or positron emission tomography/CT before CART were included. TGR was defined as change of Lugano criteria-based tumor burden between pre-BL, BL and FU1 examinations in relation to days between imaging examinations. Overall response and progression-free survival were determined based on Lugano criteria. Proportional Cox regression analysis studied association of TGR with OS. For survival analysis, OS was analyzed using Kaplan-Meier survival curves.
RESULTS
Fifty-nine out of 81 patients met the inclusion criteria. At 30-day FU1 8 patients (13.6%) had a complete response (CR), 25 patients (42.4%) a partial response (PR), 15 patients (25.4%) a stable disease (SD), and 11 patients (18.6%) a progressive disease (PD) according to CT-based Lugano criteria. The median TGR
CONCLUSION
In the context of CART, the additional use of TGR
Identifiants
pubmed: 37880181
pii: jitc-2022-006659
doi: 10.1136/jitc-2022-006659
pmc: PMC10603350
pii:
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: VBl: BMS/Celgene: Research Funding; Kite/Gilead: Consultancy, Honoraria, Research Funding; Janssen: Research Funding, Honoraria; Novartis: Research Funding, Honoraria,; Roche: Research Funding; Takeda: Research Funding. KR: Kite/Gilead: Research Funding; Kite/Gilead: Travel Support; Novartis: Honoraria. VBü: Amgen: Honoraria; Celgene/BMS: Research Funding; Kite/Gilead: Research Funding, Honoraria; Novartis: Honoraria; Pfizer: Honoraria. CS: Kite/Gilead: Travel Support. MvB-B: Astellas: Consultancy, Research Funding and Honoraria; BMS: Consultancy, Research Funding and Honoraria; Kite/Gilead: Consultancy, Research Funding and Honoraria; Miltenyi: Consultancy, Research Funding and Honoraria; Mologen: Consultancy, Research Funding and Honoraria; MSD Sharp & Dohme: Consultancy, Research Funding and Honoraria; Novartis: Consultancy, Research Funding and Honoraria; Roche: Consultancy, Research Funding and Honoraria. MS: Amgen: Research Funding, Speakers Bureau; AstraZeneca: Speakers Bureau; Aven Cell: Consultancy, BMS/Celgene: Research Funding, Speakers Bureau; CDR-Life: Consultancy, Gilead: Research Funding, Speakers Bureau; GSK: Speakers Bureau; Ichnos Sciences: Consultancy; Incyte Biosciences: Consultancy; Janssen: Research Funding, Consultancy, Speakers Bureau; Miltenyi Biotec: Research Funding, Consultancy; Morphosys: Research Funding; Molecular Partners: Consultancy; Novartis: Research Funding, Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Roche: Research Funding, Speakers Bureau; Seattle Genetics: Research Funding; Takeda: Research Funding, Consultancy, Speakers Bureau. WGK: Bristol Myers Squibb: Advisor. The remaining authors declare no competing financial interests. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.
Références
Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1406-1413
pubmed: 36513818
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Crit Rev Oncol Hematol. 2014 Apr;90(1):17-23
pubmed: 24290380
Clin Cancer Res. 2014 Jan 1;20(1):246-52
pubmed: 24240109
Acta Haematol. 2020;143(2):124-130
pubmed: 31382264
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Front Oncol. 2022 Sep 08;12:974029
pubmed: 36158658
Hemasphere. 2022 Sep 27;6(10):e781
pubmed: 36187874
Blood. 2022 Jul 28;140(4):349-358
pubmed: 35316325
Blood Adv. 2022 Jan 11;6(1):321-326
pubmed: 34700342
Ann Hematol. 2021 Sep;100(9):2303-2310
pubmed: 34236497
Leukemia. 2020 Oct;34(10):2576-2591
pubmed: 32651542
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Blood Adv. 2020 Jul 28;4(14):3268-3276
pubmed: 32702097
Ann Oncol. 2018 Aug 1;29(8):1622-1623
pubmed: 29905757
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
JAMA Oncol. 2020 Jul 1;6(7):1039-1046
pubmed: 32525513
Br J Radiol. 2021 Nov 1;94(1127):20210448
pubmed: 34379496
Ann Nucl Med. 2021 Jan;35(1):132-138
pubmed: 33174144
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):953-962
pubmed: 34480603
Clin Nucl Med. 2021 Aug 1;46(8):627-634
pubmed: 34115706
Eur J Cancer. 2011 Nov;47(17):2512-6
pubmed: 21763126
J Immunother Cancer. 2021 May;9(5):
pubmed: 33986126
J Clin Oncol. 2022 Jul 20;40(21):2352-2360
pubmed: 35357901
JCO Precis Oncol. 2020 Nov;4:829-840
pubmed: 35050757
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Transplant Cell Ther. 2021 Mar;27(3):233-240
pubmed: 33781518
Cytotherapy. 2018 Dec;20(12):1415-1418
pubmed: 30385043
Cytotherapy. 2023 Sep;25(9):986-992
pubmed: 37055322
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877